Dianthus Therapeutics to Participate in Four Investor Conferences During November

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company’s participation in four upcoming investor conferences.

Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences:

Guggenheim 2nd Annual Healthcare Innovation Conference (Boston) - Fireside chat on Tuesday, November 11, 2025 at 3:30 p.m. ET
TD Cowen Immunology & Inflammation Summit (Virtual) – Fireside chat on Wednesday, November 12, 2025 at 9:30 a.m. ET
Stifel 2025 Healthcare Conference (New York) – Fireside chat on Thursday, November 13, 2025 at 2:00 p.m. ET
Jefferies Global Healthcare Conference (London) – Corporate overview presentation on Monday, November 17, 2025 at 1.30 p.m. GMT

Webcasts of these presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.